Harbor Capital Advisors, Inc. Freeline Therapeutics Holdings PLC Transaction History

Harbor Capital Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2023	SELL	$0.42 - $0.63 $9,003 - $13,505	-21,438 Reduced 16.6%	107,731 $49,000
Q4 2022 Jan 20, 2023	SELL	$0.46 - $0.73 $1,282 - $2,035	-2,788 Reduced 2.11%	129,169 $0
Q3 2022 Oct 28, 2022	SELL	$0.69 - $1.1 $10,077 - $16,065	-14,605 Reduced 9.97%	131,957 $92,000
Q2 2022 Jul 26, 2022	BUY	$0.69 - $1.12 $1,304 - $2,116	1,890 Added 1.31%	146,562 $129,000
Q1 2022 Apr 28, 2022	SELL	$0.92 - $2.03 $34,821 - $76,833	-37,849 Reduced 20.74%	144,672 $162,000
Q4 2021 Feb 04, 2022	BUY	$1.97 - $3.45 $359,566 - $629,697	182,521 New	182,521 $360,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.